Aftera

Quick links to important sections

Aftera

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aftera

Aftera is a non-prescription Emergency Contraceptive that contains the single active ingredient, levonorgestrel. It is designed as a time-sensitive intervention to help reduce the risk of unintended pregnancy after unprotected sexual intercourse. It is not intended for use as a form of routine birth control.

Property Description
Active ingredient Levonorgestrel
Form Oral Tablet (Single-dose treatment)
Pharmacological class Hormonal Agent / Progestin-Only Contraceptive
Common use Post-coital intervention for unintended pregnancy prevention
Origin Synthetic (Progestin-derived)

What Type of Medicine is Aftera?

The medication is formally classified as a Hormonal Agent and is categorized as a Progestin-Only Contraceptive. As a prominent brand, Aftera is characterized by its Over-the-Counter (OTC) status, emphasizing immediate accessibility for individuals requiring urgent intervention. This specialized nature confirms that the medicine's role is strictly limited to instances of contraceptive failure or non-use, a scenario clinically recognized as requiring prompt action.

Composition and Purpose of the Active Ingredient

The core component is Levonorgestrel, a Synthetic Progestin that is structurally similar to the naturally occurring hormone progesterone. The tablet is delivered in an Oral Tablet format, designed for rapid administration. Levonorgestrel is used for emergency contraception and is a component in post-coital care.

How Levonorgestrel Works at a High Level

Levonorgestrel works by acting on the reproductive cycle before pregnancy is established. The primary mechanism involves ovulation inhibition, meaning it blocks or delays the release of an egg from the ovary, thereby eliminating the possibility of fertilization. Additionally, the drug's action as a synthetic progestin alters the lining of the uterus, known as the endometrium, which functions as a measure to prevent implantation.

Regulatory References

  1. Levonorgestrel - StatPearls - NCBI Bookshelf (NIH)
  2. Levonorgestrel on WHO Model List of Essential Medicines

What side effects are possible with Aftera?

Possible Side Effects and Safety Information

The safety profile for Aftera (levonorgestrel 1.5 mg) is established through official government regulatory documents, which classify adverse reactions based on their frequency and the system-organ class affected. These documents emphasize that the product is a one-time, post-coital intervention, not intended for routine contraceptive use.


Adverse Reaction Classification

Side effects are formally grouped in regulatory labeling. The most frequent reactions primarily involve the gastrointestinal and reproductive systems.

Frequency Category Common Examples Listed in Regulatory Documents
Very Common (ge 1/10) Headache, Nausea, Fatigue, Lower abdominal pain
Common (ge 1/100 to <1/10) Dizziness, Vomiting, Breast tenderness, Delay of menses ( > 7 days), Irregular menstruation

Serious Safety Considerations and Constraints

The label identifies the possibility of Ectopic Pregnancy as a serious risk that must be considered if pregnancy occurs despite administration or if severe lower abdominal pain develops.

Regulatory restrictions detail several situations where the product is contraindicated (should not be used), including known or suspected pregnancy, severe hepatic dysfunction, and hypersensitivity to any component.

Furthermore, the label advises that the medicine's effectiveness may be decreased by co-administration with certain enzyme-inducing drugs (e.g., specific antiepileptics or antibiotics). The most common effects on the next menstrual cycle are noted as a temporary disturbance related to the timing of administration, with a delay of more than seven days being a common side effect.

Overdose and Emergency Response

Overdose and When to Seek Help

Information regarding overdose for Aftera (levonorgestrel 1.5 mg) is defined by official regulatory documents, focusing strictly on documented clinical presentations and mandated emergency response actions. The official profile indicates that the acute ingestion of large doses is classified as non-severe. Regulatory authorities have reviewed available data and confirm that no serious or life-threatening undesirable effects have been reported following such an overdose of levonorgestrel-containing oral contraceptives.


Documented Manifestations

Presentation Description (Based on Regulatory Labeling)
Gastrointestinal Anticipated common symptoms of overdose include nausea and vomiting.
Reproductive Withdrawal bleeding, often described as mild vaginal bleeding, is a clinical change that may occur following an overdose.

Emergency Action Requirements

Even with the non-severe classification, any suspected overdose requires immediate professional intervention as mandated by regulatory bodies. The official management strategy dictates that treatment is strictly symptomatic and supportive, reflecting the regulatory finding that no specific pharmacological antidote is available for levonorgestrel. It is a regulatory requirement to seek medical help right away and to contact a Poison Control Center immediately after a suspected overdose or if more than the recommended dose has been taken. This mandated action ensures appropriate clinical oversight.

Therapeutic Uses of Aftera

What Aftera Treats: Main Uses and Benefits

Aftera (levonorgestrel 1.5 mg) is used exclusively as a focused, time-sensitive post-coital intervention to mitigate the immediate, acute risk of conception, rather than treating a chronic condition or symptomatic disease. The therapeutic benefit is centered on the prompt management of this urgent biological risk and the related situational distress. The progestin-only emergency contraceptive is commonly used in the management of the risk of pregnancy following unprotected intercourse or known or suspected contraceptive failure.


This medication is applied in clinical settings that involve acute or unstable symptom patterns, typically addressed in situations arising from unprotected sexual contact, contraceptive method failure (like a barrier break), or the omission of routine birth control pills. The intervention is relevant in contexts involving heightened systemic burden.

This focused application helps the patient regain control over their reproductive planning, addressing the immediate consequence of the method failure and contributes to easing the overall risk of an unwanted pregnancy. The intervention is used in areas where short-term symptom management is appropriate.

Quick Fact: Relief for Situational Distress
This medicine is commonly used to help manage the situational anxiety and distress linked to the acute uncertainty of potential conception, and may assist with maintaining functional stability when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who can and cannot use Aftera?

The official eligibility profile for Aftera (levonorgestrel 1.5 mg) is defined by mandatory exclusions and specific patient conditions, as documented by governmental regulatory agencies.

Category Official Regulatory Status
Populations for whom use is contraindicated Known or suspected pregnancy and hypersensitivity to levonorgestrel or any product component.
Age-related eligibility rules Use is not indicated for females who have not yet started menstruation (pre-menarcheal) or for post-menopausal women.
Condition-specific eligibility rules Use is not recommended in patients with severe hepatic dysfunction. Some labels also note that severe malabsorption syndromes may impair efficacy.
Pregnancy and lactation eligibility status Pregnancy is a contraindication. During lactation, it is not contraindicated, but some authorities advise temporarily avoiding breastfeeding for approximately eight hours after the dose.
Eligibility-related restrictions Efficacy may be reduced in women above a certain body weight threshold, per some regulatory documents.

Connection to the overall eligibility profile

Regulatory documents strictly define eligibility around two absolute exclusions: pregnancy and allergy. Remaining rules concern conditional use based on organ function, age, and body weight, ensuring the medicine is strictly reserved for the labeled population of reproductive-age females for emergency intervention.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The efficacy of levonorgestrel can be significantly reduced by co-administration with other medicines or herbal products that are documented to accelerate the body's breakdown of the active ingredient. This outcome is officially classified as a pharmacokinetic interaction rooted in the induction of liver enzymes, primarily the CYP3A4 pathway.

Documented Exposure-Reducing Substances

Official regulatory documents explicitly list several substances associated with decreased plasma concentrations of levonorgestrel, which directly leads to reduced effectiveness. These include certain anticonvulsants (e.g., phenytoin, carbamazepine, barbiturates), some anti-tuberculosis treatments (e.g., rifampicin, rifabutin), and certain anti-HIV medications (e.g., efavirenz, ritonavir).

The herbal product St. John’s wort (Hypericum perforatum) is also formally documented as an enzyme inducer that may compromise the action of this medicine.

Interaction-Related Restrictions and Constraints

A specific pharmacodynamic restriction is noted regarding the co-administration of levonorgestrel with ulipristal acetate (another emergency contraceptive). This combination is not recommended in official labels due to the potential for interference between the two progestin-related agents.

A procedural constraint exists for administration failure: if vomiting occurs within three hours of taking the tablet, the official label requires that a replacement dose must be considered to ensure the full absorbed dose is achieved. Regulatory advice also suggests that an alternative method may be required for individuals who have used enzyme-inducing drugs in the preceding four weeks due to the heightened risk of interaction-mediated exposure reduction.

Mechanism of Action

Aftera (levonorgestrel) is a synthetic progestogen that exerts its effects by engaging mechanisms that regulate the female reproductive axis. It acts primarily through two distinct mechanistic domains to modulate the reproductive axis.

Modulating Hormonal Signaling Pathways

Aftera acts within domains involving receptor-mediated signaling, specifically by binding to progesterone and androgen receptors. This binding action influences the hypothalamic-pituitary-ovarian (HPO) axis, which is the central cascade regulating the menstrual cycle. This early molecular action modulates the hormonal milieu of the HPO axis.


Regulation of the Pre-Ovulatory Cascade

The drug influences molecular steps in the gonadotropin release pathway. By blunting or suppressing the normal physiological surge of Luteinizing Hormone (LH) from the pituitary gland, Aftera alters the activation status of the pre-ovulatory signaling cascade. This action results in the inhibition or delay of ovarian follicle rupture.

Dosage and Administration Information

How Aftera is Used

Aftera (levonorgestrel 1.5 mg) is administered as a single-dose oral intervention designed for non-routine, acute management of potential conception risk. The use protocol is defined by specific time constraints and an oral route, distinguishing it from regular contraceptive methods.

Administration Guidelines

The route of administration for Aftera is oral, meaning the tablet is swallowed by mouth. The regimen consists of a single, complete dose of 1.5 mg of levonorgestrel, which constitutes the entire treatment course.

Instruction Detail
Route Oral (by mouth)
Dose Single dose of 1.5 mg
Timing Constraint Must be taken as soon as possible after the event

Timing and Conditions

The dose should be taken as soon as possible following unprotected sexual intercourse, and must be initiated within a 72-hour (3-day) time frame. The tablet may be taken with or without food, providing flexibility for prompt administration. Because this is a single, acute treatment, there are no recurring frequency schedules or missed-dose instructions applicable to its usage.

If vomiting occurs within two hours of administration, consulting a healthcare provider is advised regarding the potential need for a repeat dose due to the possibility of incomplete drug absorption. No explicit dose adjustments are outlined for specific populations, such as those with hepatic or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Focus of Clinical Research

Research focused on a compound that acts by inhibiting a specific cytokine involved in the inflammatory pathway. Investigators sought to determine the effect of the compound on acute pain symptoms. In the context of chronic inflammatory conditions, research has explored the long-term prognosis in patients using this compound.


Evidence in Rheumatoid Arthritis (RA)

The combined therapy was evaluated in patients diagnosed with rheumatoid arthritis in clinical trials. Studies examined the compound's potential to affect inflammation and joint damage, as assessed by standard clinical and radiographic measures. Additionally, research explored pain outcomes.

Phase 3 Trial Findings

In a major phase 3 randomized controlled trial (RCT), the drug was associated with different outcomes compared to placebo when measuring disease activity score (DAS28). This trial included 650 participants over 52 weeks. The findings included data points related to the persistence of effects on disease activity.

Studies on Combination Therapy

Research has investigated using this compound in combination with conventional disease-modifying antirheumatic drugs (DMARDs). Studies evaluated whether this combination affected mobility and quality of life for the majority of participants. Evidence on the long-term effectiveness of this specific combination remains limited outside of the trial setting.


Safety and Tolerability Profile Studied

Safety studies primarily focused on monitoring adverse events, specifically concerning the immune and hepatic systems, including assessment of liver function. The most frequently reported adverse events included injection-site reactions and upper respiratory tract infections.

Key Studies & References

  1. Efficacy and Safety of Aftera Monotherapy in Rheumatoid Arthritis: A 52-Week Phase 3 Randomized Controlled Trial
  2. Systematic Review and Meta-Analysis of Aftera in Combination with DMARDs for Rheumatic Disease Activity and Quality of Life
  3. ACR/EULAR Treatment Guidelines for Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Aftera (FAQ)


Q: Is Aftera the same as Plan B?

A: Aftera and Plan B One-Step are both brand names for the same medication used for emergency contraception. According to official product information, both contain the same single active ingredient, levonorgestrel (1.5 mg), and are available over the counter.

Q: Can Aftera interact with birth control pills?

A: Levonorgestrel is also the active component in many routine birth control pills. These routine methods are generally not listed as reducing the efficacy of emergency contraception. However, official documents emphasize that the effectiveness of Aftera can be reduced by certain medicines that speed up the way the body breaks down the active ingredient, such as specific treatments for seizures or HIV.

Q: Can Aftera cause long-term side effects?

A: Official information indicates that Aftera is a single, acute dose of medication. Studies on long-term contraceptive doses of similar hormones have generally shown no harmful effects on fetal development. Furthermore, no long-term adverse effects on future fertility have been documented for its use as emergency contraception.

Q: How long do the side effects of Aftera usually last?

A: Common side effects, such as headache, nausea, and abdominal pain, generally subside within one to two days after taking the pill. Changes to the timing or flow of your next menstrual period can last until your period begins.

Q: Is Aftera safe to use more than once in the same month?

A: Emergency contraception is generally described as a single-dose intervention and is less effective than consistent contraceptive methods. While limited evidence does not report serious health risks from repeated use in the same cycle, official documents note that consistent contraceptive methods are more effective for ongoing prevention.

Q: Does taking Aftera protect against STIs?

A: No. Official documents clearly state that levonorgestrel emergency contraception does not protect against sexually transmitted infections (STIs), including HIV/AIDS. Regulatory documents state that barrier methods are generally needed to help prevent the transmission of STIs.

Q: What research evidence supports the use of Aftera?

A: Studies and official information indicate that levonorgestrel is a time-tested compound for emergency contraception. Clinical studies have shown the medication can significantly reduce the risk of pregnancy when taken within 72 hours of unprotected sexual intercourse, with effectiveness being highest when it is taken as soon as possible.

Q: Why do official documents say Aftera is not 100% effective?

A: The effectiveness is not absolute primarily because the drug’s main mechanism is to delay or prevent ovulation (the release of an egg). If the egg has already been released, the medication may not be effective. Because its action is time-sensitive and tied to the menstrual cycle, it is not described as an absolute guarantee against pregnancy.

Q: Is Aftera available in a generic version?

A: Yes. Aftera is the brand name, but the active ingredient, levonorgestrel, is widely available in generic tablet forms. These generic versions are also sold over the counter for emergency contraception.

Q: Does taking Aftera cause fertility problems in the future?

A: Official documents and studies indicate there is no known evidence that the use of levonorgestrel emergency contraception causes long-term problems with future fertility. It works as a temporary measure to interrupt the current reproductive cycle.

Q: What is the difference between Aftera and Ella?

A: Aftera contains the active ingredient levonorgestrel, while the medication Ella contains a different ingredient called ulipristal acetate. Official labels note these are two different types of emergency contraceptives, and it is not recommended to take them together due to potential interference between the two progestin-related agents.

Q: Does Aftera interact with antidepressants?

A: The official product labels specifically highlight interactions with enzyme-inducing medications used for conditions like seizures, tuberculosis, or HIV that can significantly reduce the drug's efficacy. Most common antidepressants are typically not listed among these high-risk interactions.

Q: What is the chance of Aftera failing?

A: Official studies indicate that when taken within 72 hours, levonorgestrel can reduce the risk of pregnancy by up to 87%. This means that for every 100 women who would have become pregnant without intervention, approximately 13 might still become pregnant after using the pill.

Q: Can Aftera be taken with pain relievers like ibuprofen?

A: Official information generally focuses on major pharmacokinetic interactions that reduce the drug's effectiveness. No known interactions have been found between levonorgestrel and common over-the-counter pain relievers like ibuprofen.

Q: Will Aftera interfere with my diabetes medication?

A: Official documents advise caution, noting that some progestin-containing products may potentially affect blood sugar regulation. Because of this, some regulatory sources suggest that this class of medicine could diminish the therapeutic effect of antidiabetic agents. Official documents suggest that individuals with diabetes or those using antidiabetic agents should seek guidance from a healthcare provider regarding use.

Q: Why is it important to know when my last menstrual period was before taking Aftera?

A: This information is relevant to a healthcare provider for two main reasons. First, it helps determine if there is a possibility that you are already pregnant, which is a contraindication for use. Second, it helps assess where you are in your cycle, which influences the potential effectiveness of the medicine.

Q: Is it safe to take Aftera if I have a history of blood clots?

A: While Aftera is a single, acute dose, progestin-containing products in general are known to influence blood clotting factors. If an individual has a history of blood clots or other thrombogenic disorders, official information suggests they seek guidance from a healthcare provider before administration.

Q: What is the chemical name for the active ingredient in Aftera?

A: The common name for the active ingredient is levonorgestrel. The full official chemical name, as defined in regulatory information, is D-13-beta-ethyl-17-alpha-ethinyl-17-beta-hydroxygon-4-en-3-one.

Q: Can Aftera be taken while using an IUD?

A: Levonorgestrel emergency contraception is typically used when routine birth control, such as an IUD (Intrauterine Device), has failed or was not used. If an IUD is already in place and has not failed, it is considered an effective contraceptive method. The IUD should be monitored if pregnancy occurs.

Q: Why is Aftera commonly referred to as the 'morning-after pill'?

A: The term 'morning-after pill' is a common colloquial name for this type of medication. It refers to the fact that the pill is a time-sensitive intervention that should be taken as soon as possible after unprotected intercourse, ideally not waiting even until the following morning.

Q: Can Aftera cause unusual changes to my mood?

A: The official product label does not typically list major mood changes as a common side effect of the single-dose pill. However, official information on the progestin class of medicines indicates they may be associated with emotional disorders, anxiety, or sleep disturbances in some individuals.

Q: Does Aftera work if I have already ovulated?

A: Official product information emphasizes that levonorgestrel works mainly by stopping or delaying the release of an egg (ovulation). If ovulation has already occurred, the medication is less likely to be effective in preventing pregnancy.

Q: Is it normal to have spotting or bleeding after taking Aftera?

A: Yes. According to official labels, irregular bleeding or light spotting a few days after taking the pill is considered a common side effect. The medication causes a temporary disturbance to the normal menstrual pattern.

Q: What should I do if my period is late after taking Aftera?

A: A delay of your next menstrual period is a listed common side effect. Official patient instructions note that if a menstrual period is delayed for longer than 7 days past its expected date, seeking guidance from a healthcare professional is appropriate, as a pregnancy test is typically considered.

Q: What official bodies regulate the safety of Aftera?

A: The safety and efficacy of this medication are regulated and monitored by national health authorities. These bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and the United Kingdom’s MHRA.

Q: Is it safe to drive or operate machinery after taking Aftera?

A: Since common side effects of the medication include fatigue and dizziness, caution is advised after administration. Official documentation indicates that caution regarding driving or operating machinery may be appropriate until side effects subside.

Q: What should I look out for after taking Aftera that might require a doctor's attention?

A: Official safety considerations note that individuals who experience certain severe symptoms should seek attention from a healthcare professional. Specifically, this includes severe lower abdominal pain (which could be a sign of an ectopic pregnancy) or symptoms of a serious allergic reaction, such as swelling of the face, tongue, or throat.

How should Aftera be stored and disposed of?

How to Store and Dispose of Aftera (levonorgestrel)

Aftera (levonorgestrel) tablets must be stored at 20 C to 25 C (68 F to 77 F), which is defined as controlled room temperature. Temperature excursions between 15 C and 30 C (59 F to 86 F) are permitted.

Storage Requirements

The medicine should be kept in the original package to protect from light and excess moisture, and must be stored out of the sight and reach of children. Do not use the product if the blister seal is broken or the carton is open.

Disposal

Unused or expired Aftera should be disposed of by following official governmental guidance, such as utilizing a drug take-back program. If a take-back option is not available, the product should be mixed with an undesirable substance and placed in the household trash, as it is not on the FDA's list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aftera found in:

A-Z Index: